14 December 2021 in Head and Neck Tumors (HNT)
Epidermal growth factor receptor inhibitors (EGFR) have a high rate of class-specific dermatologic adverse events. Supportive treatment of dermatologic adverse events decreases their severity, minimizes the need for dose de-escalation / discontinuation of targeted therapy, improves commitment to anticancer treatment and patient’s quality of life. Close interdisciplinary cooperation between oncologists and dermatologists is a key to the successful management of patients treated with EGFR. This article highlights current approaches to classification, concepts of pathogenesis and clinical course of EGFR-associated dermatologic adverse events, current and promising prophylactic and therapeutic strategies to manage these adverse events.
12 August 2023 in Fizioterapevt (Physiotherapist)
MFMoscow Federal State Budgetary Institution Of Continuous Professional Education «Central State Medical Academy» Of The Presidential Administration Of The Russian Federation
Moscow Federal State Budgetary Institution Of Continuous Professional Education «Central State Medical Academy» Of The Presidential Administration Of The Russian Federation
MCMoscow Aksma Limited Liability Company
Moscow Aksma Limited Liability Company
The article presents the results of a comparative assessment of the effectiveness of the course application of therapeutic physical factors (alternating magnetic field and low-intensity laser radiation) in complex medical rehabilitation of patients with moderate and severe rhinosinusitis polyposa with uncontrolled course. It was shown that the use of genetically engineered biological therapy (GEBT) with dupilumab contributed to the positive dynamics of the clinical parameters of sinonasal polyposis. Complementing GEBT with the course application of an alternating magnetic field was accompanied by an increase in the regression of the main clinical manifestations of rhinosinusitis polyposa. The maximum corrective activity was noted in the group with the complex use of therapeutic physical factors — an alternating magnetic field and low-intensity laser radiation against the background of GEBT. The growth is based on the ability of the complex use of physiotherapeutic factors to cause the development of synergistic phenomena through the use of corrective effects of different modality, having different mechanisms of action. The physical factors under consideration are able to improve hemo- and microcirculation in the area of chronic inflammation, exhibit anti-inflammatory, analgesic, and trophic-stimulating effects, which, together with the inactivation of the main pro-inflammatory interleukins of type 2 inflammation, enhances the sanogenetic potential that determines the duration of remission. Taking into account the chronic relapsing nature of the rhinosinusitis polyposa course, it is planned to conduct prolonged studies covering a follow-up period of 1.5–2 years.
28 November 2022 in Medical alphabet
Introduction. The drug netakimab belongs to the group of IL-17A blockers and has shown high efficacy against all clinical symptoms of psoriasis vulgaris according to clinical trials and real clinical practice. At the same time, data on the effectiveness of netakimab in inverse psoriasis, psoriasis of ‘difficult’ localizations are of a single nature, while these phenotypes, as a rule, proceed torpidly and constantly recur, which makes it possible to attribute them to severe forms and to consider the appointment of genetically engineered drugs in the first line of systemic treatment.Material and methods. The study included 68 patients with various localizations of psoriasis vulgaris (scalp, palms and soles), psoriatic onychodystrophy and inverse psoriasis. Psoriasis vulgaris with lesions of the scalp was observed in 28 (41.2%) patients, with lesions of the palms and soles – in 24 (35.3%). Inverse psoriasis was diagnosed in 37 (54.4%) patients. Psoriatic onychodystrophy was observed in 44 (64.7%) patients and was combined with both psoriasis vulgaris and inverse psoriasis. All patients were prescribed netakimab.Results. In the group of patients with inverse psoriasis, 81.1% of patients achieved sPGA scores of 0 after 12 weeks. In 71.4% of patients with psoriasis of the scalp, in 75% of patients with palmar-plantar psoriasis, it was possible to achieve complete control over the disease sPGA 0 points. The number of patients with NAPSI less than 5 points was 70.5%.Conclusions. The data presented in the article confirm the high efficacy of netakimab in the treatment of scalp psoriasis, palmoplantar psoriasis, with inverse forms and psoriatic onychodystrophy.
22 December 2019 in Almanac of Clinical Medicine
Psoriasis and inflammatory bowel disease (IBD) are multifactorial chronic immuno-inflammatory potentially disabling disorders with similar genetic factors and immunological pathways, in particular, genetic polymorphisms of IL-23R, which determines the signal IL-12/23-mediated pathway of immunopathogenesis. The emergence of genetically engineered biological agents has changed the prognosis for both psoriasis and IBD. The intersection of the therapeutic spectrum in psoriasis and IBD is a very important point when choosing the management strategy for these patients. Infliximab and adalimumab are effective in the treatment of psoriasis, psoriatic arthritis, Crohn's disease, ulcerative colitis (evidence level 1A). Ustekinumab demonstrates effectiveness in the treatment of psoriasis, psoriatic arthritis (evidence level 1A) and Crohn's disease (evidence level 1B). Etanercept and secukinumab have been shown to be effective against psoriasis, psoriatic arthritis (evidence level 1A) and ineffective and even associated with exacerbation risk in Crohn's disease and ulcerative colitis. Inhibition of regulatory cytokines IL-12/23 also has a number of advantages compared to the blockade of effector cytokines (TNF-α, IL-17) due to potentially long-term and stable treatment results and less frequent administration.
11 November 2021 in Oncohematology
Therapy with epidermal growth factor receptor (EGFR) inhibitors is inevitably accompanied by the phenomena of dermatological toxicity. Being, on the one hand, a favorable prognostic factor for the effectiveness of anticancer therapy, these adverse events are one of the most frequent indications for treatment withdrawal. This article presents the clinical characteristics of a wide spectrum of dermatological adverse events, as well as the pathogenetic rationale for their correction. Algorithms for prescribing of external and systemic therapy based on the assessment of severity of skin lesions and skin appendages involvement are presented.
28 November 2022 in Medical alphabet
A practicing physician always faces a rather difficult task when choosing a topical drug for the treatment of mycoses, while the optimal ratio of efficacy/safety and a wide spectrum of action, including against possible contamination by various pathogens, can be considered a priority factor. Sertaconazole (Zalain) is a highly active broad-spectrum antifungal drug that has fungicidal, antibacterial, anti-inflammatory and antipruritic effects.Material and methods. On an outpatient basis, under our supervision were 25 patients aged 42 to 76 years with a verified diagnosis of foot mycosis, confirmed by microscopic and cultural methods. All patients were prescribed Zalain cream 2 times a day for 4 weeks.Results. After therapy (4 weeks), pathogenic fungi (T. rubrum, T. mentagrophytes var. interdigitale) were not sown in 92% of patients during a cultural study. 8% of patients with no laboratory cure were recommended to continue sertaconazole therapy for 2–4 weeks until complete eradication of pathogenic fungi. Long-term results of observations (6 months) showed no recurrence of the disease in 100% of patients.Conclusions. The high efficacy and safety of Zalain in the treatment of skin mycoses has been proven in numerous studies and confirmed by real clinical practice, which allows us to recommend it for the treatment of patients with this pathology, including in cases of secondary infection and eczematization.